About Thinq Pharma-Cro Limited
Data last updated:
Thinq Pharma-Cro Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 10 November 2006 and has been in existence for over 20 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN U24239MH2006PLC165473. Its GSTIN is 27AACCT5411D1ZQ (Maharashtra). The company holds 5 GST registrations, of which 4 are active.
The company has an authorised share capital of ₹25 Lakh and a paid-up capital of ₹5.01 Lakh. It is led by directors including Chandrashekhar Shankar Nadkarni (Managing Director) and Ravindra Ramakant Gulgule.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at D – 3 1st Floor Daginawala Mansion S. B. Rd Mahim – West, Mumbai, Maharashtra, India – 400016.
As per the financials filed for FY 2025, the company reported a revenue of ₹62.89 Cr, a growth of 17% compared to the previous year. For the same year it recorded a net profit of ₹3.97 Cr (net margin 6.3%) and EBITDA of ₹10.91 Cr (EBITDA margin 17.3%). Revenue has grown at a compounded annual rate (CAGR) of 1% over five years.
The company has about 148 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: THINQ Pharma. As per MCA filings, the company has open charges of ₹48.38 Cr and satisfied charges of ₹85.95 Cr on record. Court records list 4 cases involving the company, including 3 filed by the company and 1 filed against it; 3 cases are pending. The company has 4 deals on record (4 secondary share transfers); the latest was in October 2024. Its 9 peer companies in the Pharma industry (Contract Research, Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 4 larger and 5 smaller; the largest is Adley Lab Limited with revenue of ₹63.38 Cr.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website thinqcro.com.
Company details
Contact details
Thinq Pharma-Cro Limited's registered office is in Mumbai, Maharashtra. Its website is thinqcro.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered AddressD – 3 1st Floor Daginawala Mansion S. B. Rd Mahim – West, Mumbai, Maharashtra, India – 400016
- IndustryPharma, Drug Formulation & Development, Pharma Contract R&D
To see the full contact details of Thinq Pharma-Cro Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Thinq Pharma-Cro operates one associated brand: THINQ Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Manufactures pharmaceutical formulations, APIs, and offers R&D and regulatory services worldwide. | thinqcro.com |
Business activity
The main business activities of Thinq Pharma-Cro are manufacturing and support service to organizations. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products and other support services to organizations. 2 activity segments are registered with the MCA.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | |
| N | Support service to Organizations | N7 | Other support services to organizations |
To see the full business activity and turnover split of Thinq Pharma-Cro Limited, buy the company report.
Financials of Thinq Pharma-Cro Limited
FY 2025 filings availableThinq Pharma-Cro Limited reported revenue of ₹62.89 Cr (up 17% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 1% over five years, including 17% growth in the latest year. EBITDA fell 9% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹10.91 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹3.97 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 17.3% | ||||
| Net Profit Margin | 6.3% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Thinq Pharma-Cro Limited, buy the company report.
Board of directors of Thinq Pharma-Cro Limited
Thinq Pharma-Cro has 3 current directors and 2 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Chandrashekhar Shankar Nadkarni | Managing Director | 10 Nov 2006 | 19 Years 11 Months | Current |
| Ravindra Ramakant Gulgule Also directs: Phamunico LLP, Aapar Nutripham Private Limited, Altique Cosmoscience Private Limited and 1 more | Director | 15 Sep 2011 | 15 Years 1 Months | Current |
| Rohit Ramakant Gulgule | Director | 10 Nov 2006 | 19 Years 11 Months | Current |
Peer comparison
Thinq Pharma-Cro Limited is compared with the 9 companies closest to it by revenue in the Pharma industry (Contract Research, Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Adley Lab Limited | ₹63.38 Cr (FY 2025) | 19.0% | Derabassi, Punjab, India | |||
| Cooper Pharma Limited | ₹63.28 Cr (FY 2024) | -1.0% | Delhi, India | |||
| Althea Pharma Private Limited | ₹63.27 Cr (FY 2024) | 14.0% | Vapi, Gujarat, India | |||
| Onyx Biotec Limited | ₹63.12 Cr (FY 2025) | 17.0% | Solan, Himachal Pradesh, India | |||
| Thinq Pharma-Cro Limitedthis company | ₹62.89 Cr (FY 2025) | ₹3.97 Cr | 6.3% | 17.0% | 148 | Mumbai, Maharashtra, India |
| Preet Remedies Limited | ₹62.83 Cr (FY 2025) | 18.0% | Chandigarh, India | |||
| Sri Gayathri Drugs Private Limited | ₹62.48 Cr (FY 2025) | 15.0% | Hyderabad, Telangana, India | |||
| Terratech Intermediates (India) Private Limited | ₹62.41 Cr (FY 2025) | 59.0% | Ahmedabad, Gujarat, India | |||
| Shamshree Lifesciences Limited | ₹62.27 Cr (FY 2025) | 10.0% | Chandigarh, India | |||
| Cian Healthcare Limited | ₹62.14 Cr (FY 2024) | -10.0% | Pune, Maharashtra, India |
To see the full peer comparison of Thinq Pharma-Cro Limited, buy the company report.
Auditor
Thinq Pharma-Cro Limited is audited by G. J. SHAH & COMPANY for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| G. J. SHAH & COMPANY | FY 2024 | 02829C |
Shareholding
The shareholding of Thinq Pharma-Cro Limited is on record for 5 financial years, the latest being FY 2024, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2024 | FY 2023 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Thinq Pharma-Cro Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 31 Oct 2025 | 101203004 | Others | ₹1.44 Cr | Open | |
| 30 Oct 2025 | 101182815 | Standard Chartered Bank | ₹8.5 Cr | Open | |
| 17 Jun 2025 | 101125446 | Standard Chartered Bank | ₹12 Cr | Open | |
| 30 Jan 2025 | 101093769 | Others | ₹74.21 Lakh | Open | |
| 08 Feb 2024 | 100873331 | Others | ₹5.7 Cr | Open |
To see the full charge records of Thinq Pharma-Cro Limited, buy the company report.
Total charge records: 21 View all charges
Deals & funding
Thinq Pharma-Cro Limited has 4 deals on record (4 secondary share transfers); the latest was in October 2024.
Deals on record (4 of 4)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Oct 2024 | Secondary share transfer | Undisclosed | Buyer: 2 individuals Seller: an individual |
| Mar 2015 | Secondary share transfer | Undisclosed | Buyer: 4 individuals Seller: 2 individuals |
| Mar 2013 | Secondary share transfer | Undisclosed | Buyer: 3 individuals Seller: 3 individuals |
| Sep 2008 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Thinq Pharma-Cro Limited has 4 court cases on record: 3 filed by Thinq Pharma-Cro, 1 filed against it. 3 cases are pending and 1 is disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 3 | 0 | 2 |
| High courts | 1 | 1 | 1 |
Cases on record (4 of 4)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Thane, Maharashtra | Civil suit | Filed by the company against M/S Spruhaa Healthcare Private Limited | Pending |
| District court, Thane, Maharashtra | Civil suit | Filed by the company against Anamayee Pharmachem Pvt. Ltd. | Pending |
| District court, Mumbai CMM Courts, Maharashtra | Civil suit | Filed by the company against Anamayee Pharmachem Pvt Ltd and Anuradha Chaudhary | Disposed |
| Bombay High Court | Writ petition | Filed against the company by Ananmayee Pharmachem Private Limited and Anr | Pending |
To see the full case history of Thinq Pharma-Cro Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Thinq Pharma-Cro Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Thinq Pharma-Cro Limited has a workforce of 148 employees on its EPFO records as of Nov 07, 2025, across 1 active EPFO establishment.
GST
Thinq Pharma-Cro has 5 GST registrations: 4 active and 1 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AACCT5411D1ZQ | Maharashtra | Active | 01 Jul 2017 |
| 23AACCT5411D1ZY | Madhya Pradesh | Active | 01 Jul 2017 |
| 37AACCT5411D1ZP | Andhra Pradesh | Active | 01 Jul 2017 |
| 24AACCT5411D1ZW | Gujarat | Active | 21 Aug 2018 |
To see the full GST registrations and return filing status of Thinq Pharma-Cro Limited, buy the company report.
Recent activity
Thinq Pharma-Cro Limited has 5 board changes on record since 2006: 3 appointments and 2 cessations. The latest: Shibani Chandrashekhar Nadkarni ceased to be Director on 18 May 2024.
37 earlier events are in the company report.
Frequently asked questions
Thinq Pharma-Cro is an active public limited company based in Mumbai, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 10 November 2006 (20+ years old) and is registered under CIN U24239MH2006PLC165473.
Thinq Pharma-Cro has 3 current directors:
- Chandrashekhar Shankar Nadkarni - Managing Director
- Ravindra Ramakant Gulgule - Director
- Rohit Ramakant Gulgule - Director
The latest financial statements of Thinq Pharma-Cro on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 30 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Thinq Pharma-Cro is 27AACCT5411D1ZQ, registered in Maharashtra. The company has 5 GST registrations in all, of which 4 are active and 1 is cancelled or inactive. Other active GSTINs include 23AACCT5411D1ZY (Madhya Pradesh), 37AACCT5411D1ZP (Andhra Pradesh), 24AACCT5411D1ZW (Gujarat).
The CIN (Corporate Identification Number) of Thinq Pharma-Cro is U24239MH2006PLC165473. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Thinq Pharma-Cro has 4 court cases on record: 3 filed by the company and 1 filed against it. 3 are pending. Most are in the district courts.
Thinq Pharma-Cro was incorporated on 10 November 2006, making it 20+ years old. It is registered with the Registrar of Companies, Mumbai.
Thinq Pharma-Cro has 4 deals on record (4 secondary share transfers); the latest was in October 2024.
The peers of Thinq Pharma-Cro by revenue are Adley Lab Limited, Cooper Pharma Limited, Althea Pharma Private Limited, Onyx Biotec Limited, Preet Remedies Limited and 4 more, all in the Pharma industry (Contract Research, Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Shibani Chandrashekhar Nadkarni ceased to be Director on 18 May 2024. Girish Suresh Virkar ceased to be Director on 30 Sep 2011. Ravindra Ramakant Gulgule was appointed as Director on 15 Sep 2011. Thinq Pharma-Cro has 5 board changes on record in total.
Thinq Pharma-Cro can be reached through the website thinqcro.com. Its registered office is in Mumbai, Maharashtra, India.